Vertex Pharmaceuticals
VRTX
951 hedge funds and large institutions have $66B invested in Vertex Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 92 funds opening new positions, 406 increasing their positions, 319 reducing their positions, and 96 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 406 | Existing positions reduced: 319
0.74% less ownership
Funds ownership: 93.91% → 93.18% (-0.74%)
4% less first-time investments, than exits
New positions opened: 92 | Existing positions closed: 96
1% less funds holding
Funds holding: 964 → 951 (-13)
7% less capital invested
Capital invested by funds: $70.6B → $66B (-$4.67B)
15% less call options, than puts
Call options by funds: $237M | Put options by funds: $279M
26% less funds holding in top 10
Funds holding in top 10: 27 → 20 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$252M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$240M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$224M |
| 4 |
Goldman Sachs
New York
|
+$150M |
| 5 |
HM
HealthCor Management
New York
|
+$92.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$311M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$228M |
| 3 |
Jennison Associates
New York
|
-$223M |
| 4 |
Renaissance Technologies
New York
|
-$158M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$123M |
VRTX Hedge Fund Activity: Q3 2020 in Review
951 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2020, worth a combined $66B — down 6.6% from $70.6B a quarter earlier.
Sellers outnumbered buyers: 96 funds closed out of VRTX and 92 opened new positions — a net loss of 4 holders — while 319 trimmed existing stakes and 406 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $252M. The largest seller was Capital World Investors, cutting an estimated $311M.
- 951 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2020, down from 964 in Q2 2020.
- Funds reported $66B of Vertex Pharmaceuticals stock for Q3 2020, down 6.6% quarter-over-quarter.
- 92 funds opened new Vertex Pharmaceuticals positions in Q3 2020 and 96 closed out, a net change of -4 holders.
- The largest Vertex Pharmaceuticals buyer in Q3 2020 was Citadel Advisors, an estimated $252M added.
- The largest Vertex Pharmaceuticals seller in Q3 2020 was Capital World Investors, an estimated $311M sold.
Based on aggregated 13F filings for Q3 2020.